LUKAS SCHEIBLER - 01 Apr 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: CHIEF INNOVATION OFFICER
Signature: /s/ David Watson, attorney-in-fact for Lukas Scheibler
Issuer symbol: APLS
Transactions as of: 01 Apr 2022
Net transactions value: -$473,635
Form type: 4
Filing time: 04 Apr 2022, 17:03:19 UTC
Previous filing: 15 Feb 2022
Next filing: 05 Apr 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Options Exercise	$159,220	+11,496	+22%	$13.85	63,729	01 Apr 2022	Direct	F1
transaction	APLS	Common Stock	Sale	$632,855	-11,496	-18%	$55.05	52,233	01 Apr 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Options Exercise	$0	-11,496	-18%	$0.000000	53,504	01 Apr 2022	Common Stock	11,496	$13.85	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This is a scheduled exercise and sale from 10B5-1 trading plan.
F2	The sale price range within $1.00. Max. $55.12 - Min. $55.00
F3	This represents a stock option grant made on 02/08/2019 that vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service.